Validation of International Working Group response criteria in higher‐risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium
Abstract The utility of the International Working Group (IWG) 2006 response criteria for myelodysplastic syndromes (MDS) as a surrogate endpoint for outcomes is unclear. We assessed the validity of the IWG 2006 response criteria in a large cohort of higher‐risk MDS patients (pts) treated at centers...
Main Authors: | Rami S. Komrokji, Najla H Al Ali, David Sallman, Eric Padron, Amy E. DeZern, John Barnard, Gail J. Roboz, Guillermo Garcia‐Manero, Alan List, David P. Steensma, Mikkael A. Sekeres |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-01-01
|
Series: | Cancer Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/cam4.3608 |
Similar Items
-
Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): a state-of-the-art report on behalf of the International Consortium for MDS (icMDS)
by: Stahl, M, et al.
Published: (2023) -
S170: MYELODYSPLASTIC NEOPLASMS (MDS) CLASSIFICATION FROM WHO 2017 TO WHO 2022 AND ICC 2022): AN EXPANDED ANALYSIS OF 7017 PATIENTS ON BEHALF OF THE INTERNATIONAL CONSORTIUM FOR MDS (ICMDS)
by: Rami S. Komrokji, et al.
Published: (2023-08-01) -
Myelodysplastic Neoplasms (MDS): The Current and Future Treatment Landscape
by: Daniel Karel, et al.
Published: (2024-04-01) -
Toward a more patient‐centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS)
by: Fabio Efficace, et al.
Published: (2024-05-01) -
Myelodysplastic syndromes (MDS): prognostic factors and scoring systems
by: Elizabeth Xisto Souto, et al.